Speaker 1: H Hi Tracy.
Speaker 2: Hello everyone. I'm Valerie Bowling and I'm the executive director
Speaker 2: of the conference Forum. I'm with the director of DEFARM,
Speaker 2: Tracy Kimball, and today we're going to talk about AI
Speaker 2: and we're doing a just a brief series of really
Speaker 2: like vignettes on what you can expect at the fifteenth
Speaker 2: annual DEFARM.
Speaker 1: This is a celebration year for US. DEFARM was launched.
Speaker 2: Obviously fifteen years ago, and it was launched really with
Speaker 2: the idea of how can we disrupt the way we
Speaker 2: do clinical research to make it far more efficient, focusing
Speaker 2: on automation ultimately focusing of course on the patient, how
Speaker 2: to reduce that burden, how to be better partners to
Speaker 2: our sites and reduce the bird to them as well.
Speaker 2: So the ultimate really the description, if you will, of
Speaker 2: the definition of disruption is how do you make something
Speaker 2: more convenient and less expensive in its simplest form, if
Speaker 2: you will. So how do we actually apply that to
Speaker 2: clinical research? And that's what DEFARM is about. So we
Speaker 2: focus on how can we bring forward innovation, new ideas,
Speaker 2: how can we leap frog these into execution and inspire
Speaker 2: the clinical trial operations community. So it is about ultimately
Speaker 2: as well modernizing way we do clinical trials. So we
Speaker 2: have a bar to reach every year, of course, and
Speaker 2: somehow we do it and Tracy leads the way on
Speaker 2: doing that. So today we want to talk about AI
Speaker 2: because obviously AI is the probably the hugest topic going.
Speaker 2: But what does it really mean? What does it really
Speaker 2: do for you? What's real, what's annoying, what's not really
Speaker 2: going to help you? That's important and we know that
Speaker 2: AI is going to be in everything. So for example,
Speaker 2: I was reading an article the other day about how
Speaker 2: AI will be in refrigerators and toasters and everyone's going
Speaker 2: to know how many times you open that fridge and
Speaker 2: turn that toaster on. Anyhow, it's our future and it's
Speaker 2: huge and it's everywhere. But what is it really doing
Speaker 2: for us in clinical trial operations? And what can we
Speaker 2: bring forward that will actually be useful and helpful in
Speaker 2: the work that you're doing. So Tracy, with that, I
Speaker 2: want to ask you if you can tell us a
Speaker 2: little bit about what we can expect for AI this year.
Speaker 1: Yeah. Absolutely, I'd like to talk about the.
Speaker 3: Three sessions in particular, there are many sessions, as you
Speaker 3: said that we'll be talking about how clinical operations. Teams
Speaker 3: are integrating EAI machine learning throughout clinical trial operations to
Speaker 3: do just as what we've been talking about, automating and
Speaker 3: accelerating clinical trials.
Speaker 1: But we are so fortunate to have Don Tampy, who
Speaker 1: is the head of Global Introbated Clinical Data from Mark,
Speaker 1: unveiling their strategy for automating clinical trial operations. Don was
Speaker 1: just tasked with this with this.
Speaker 3: Mandate and it is a timely mandate for them that
Speaker 3: they want to accelerate, and he will be presenting on
Speaker 3: their initial validated strategy along with the initial roadmap.
Speaker 1: They have and early readouts.
Speaker 3: The exciting disruptive thing that will be happening at Defarmers
Speaker 3: will be using AI through that.
Speaker 1: Session to take the feedback.
Speaker 3: Then people will that our Defarm audience will be able
Speaker 3: to give Don throughout the session, analyze that feedbacks and
Speaker 3: report back on that during the session to kind of
Speaker 3: see how industry or our audience thinks that perhaps.
Speaker 1: The pass forward should include X, Y and D. So
Speaker 1: it's a very exciting session.
Speaker 3: We are delighted to have DONA and Mark representative bring
Speaker 3: this session to DEFARM. So that's day one, the warning
Speaker 3: of day one, and that Day two, we have to
Speaker 3: senior leadership AI sessions. The first one looking at generative
Speaker 3: AI from the perspective of lining aligning your resources with ROI.
Speaker 3: We have an excellent panel with Barry Call from Regeneron
Speaker 3: as our moderator.
Speaker 1: We have Faisal Koon who spoke last.
Speaker 3: Year at DEFARM as a panelist from nov norns, Suba
Speaker 3: Matt Hoven who is the VP of AI, and M
Speaker 3: L within R and d Cross Busor and then a
Speaker 3: new a new leader of these NASA from Insight who's
Speaker 3: the head of their AI innovations institutes, and they'll really
Speaker 3: be looking at use cases where it's being used, the
Speaker 3: impact that we're seeing on you know, costs, timelines, speed,
Speaker 3: efficiencies as well as kind of thinking about it from
Speaker 3: the perspective of you know, impacts and you know, what
Speaker 3: kind of talent will you need to have in house
Speaker 3: to to really capitalize on genit of AI.
Speaker 1: And then we'll go from that session right into another
Speaker 1: AI session that's looking at a gentic AI and what
Speaker 1: the potential how it can potentially revolutionize trial operations.
Speaker 3: Level setting sort of on you know what people are
Speaker 3: seeing as the you know the definitions of agentic AI
Speaker 3: agentic AI architecture and where it's being used, the impact
Speaker 3: and that session also has an incredible group of folks
Speaker 3: in discussing.
Speaker 1: We have Angela de.
Speaker 3: Ludegaws, the head of Global Study Operation at MJAM, as
Speaker 3: well as panelists that include Sid Hyder who is from
Speaker 3: murp AND's Room, the head of their business ITAA Partnerships,
Speaker 3: u su Bidalcaid who's the head of the AI Research
Speaker 3: Center at Gilead, and Henry Way from Regeneral's the head
Speaker 3: of development Innovation. So three really strong, exciting sessions looking
Speaker 3: at AI. So very nice job.
Speaker 2: And so we have September sixteenth and seventeenth at the
Speaker 2: Low's Philadelphia Hotel. I'm happy to say we have the
Speaker 2: whole hotel Lasty we only had part of it, so
Speaker 2: we have much more space.
Speaker 1: And the day before.
Speaker 2: DFARM, we're also running a conference called Partnerships with Sites,
Speaker 2: as well as our CRACO event, which is also having
Speaker 2: an anniversary year. It's its tenth year, and that's Clinical
Speaker 2: Research as a Care Option and they're going to share
Speaker 2: the same networking those two events because they have a
Speaker 2: lot of overlap. All right, So Tracy, thank you so much,
Speaker 2: and obviously will continue our series and looking at different
Speaker 2: sections of deforming, what it will do and how it
Speaker 2: will help folks in clinical trial operations.
Speaker 1: So thanks so much, thanks